Carglumic acid is an orphan drug, marketed by Orphan Europe under the trade name Carbaglu. Carglumic acid is used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. The initial daily dose ranges from 100 to 250 mg/kg, adjusted thereafter to maintain normal plasma levels of ammonia.
Verardo, Giancarlo; Geatti, Paola; Strazzolini, Paolo Synthetic Communications Volume 37 Issue 11 Pages 1833-1844 Journal 2007
Liu, Yaqian; Yang, Hao; Xiang, Yang Jingxi Huagong Zhongjianti Volume 41 Issue 1 Pages 29-31, 48 Journal 2011
Qiao, Shiyan; Yue, Longyao; Huang, Xuebin; Wang, Chunping. Method for preparing N-carbamylglutamic acid. Assignee Beijing Longkefangzhou Biology Engineering Center, Peop. Rep. China. CN 101440042. (2009).
Shu, Xugang; Gao, Junyong; Xu, Xiang; Yin, Yulong. Zinc n-aminoformyl-l-glutamate complexes and the preparation method thereof. Assignee Guangzhou Jiuyi Biotechnology Co., Ltd., Peop. Rep. China. CN 102603778. (2012).
Cao, Fei; Li, Wenhui; Wu, Hongli; Tang, Zhiqun; Hong, Weiming; Lu, Hui. Method for crystallizing N-carbamyl-glutamic acid by acidifying with mixed acid. Assignee Nanjing Tech University, Peop. Rep. China. CN 105601542. (2016).
